Vale SA ADR (VALE)vsVersamet Royalties Corporation Common Stock (VMET)
VALE
Vale SA ADR
$15.71
-3.42%
BASIC MATERIALS · Cap: $65.65B
VMET
Versamet Royalties Corporation Common Stock
$11.16
-5.39%
BASIC MATERIALS · Cap: $1.26B
Smart Verdict
WallStSmart Research — data-driven comparison
Vale SA ADR generates 388618% more annual revenue ($214.86B vs $55.27M). VMET leads profitability with a 58.4% profit margin vs 7.3%. VALE trades at a lower P/E of 23.4x. VALE earns a higher WallStSmart Score of 67/100 (B-).
VALE
Strong Buy67
out of 100
Grade: B-
VMET
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+77.0%
Fair Value
$75.47
Current Price
$15.71
$59.76 discount
Intrinsic value data unavailable for VMET.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 28.1%
Earnings expanding 22.0% YoY
Keeps 58 of every $100 in revenue as profit
Strong operational efficiency at 90.6%
Revenue surging 594.0% year-over-year
Earnings expanding 573.0% YoY
Conservative balance sheet, low leverage
Areas to Watch
2.7% revenue growth
ROE of 7.6% — below average capital efficiency
7.3% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : VALE
The strongest argument for VALE centers on PEG Ratio, Market Cap, Price/Book. PEG of 0.32 suggests the stock is reasonably priced for its growth.
Bull Case : VMET
The strongest argument for VMET centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 58.4% and operating margin at 90.6%. Revenue growth of 594.0% demonstrates continued momentum.
Bear Case : VALE
The primary concerns for VALE are Revenue Growth, Return on Equity, Profit Margin.
Bear Case : VMET
The primary concerns for VMET are P/E Ratio, Market Cap, Altman Z-Score.
Key Dynamics to Monitor
VALE profiles as a value stock while VMET is a growth play — different risk/reward profiles.
VMET is growing revenue faster at 594.0% — sustainability is the question.
VALE generates stronger free cash flow (700M), providing more financial flexibility.
Monitor OTHER INDUSTRIAL METALS & MINING industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VALE scores higher overall (67/100 vs 58/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Vale SA ADR
BASIC MATERIALS · OTHER INDUSTRIAL METALS & MINING · USA
Vale SA produces and sells iron ore and iron ore pellets for use as raw material in steelmaking in Brazil and internationally. The company is headquartered in Rio de Janeiro, Brazil.
Versamet Royalties Corporation Common Stock
BASIC MATERIALS · OTHER PRECIOUS METALS & MINING · USA
Viamet Pharmaceuticals Corp (VMET) is a biopharmaceutical company focused on developing cutting-edge therapeutics for serious diseases, leveraging its proprietary metalloenzyme-based technology platform. The company is committed to addressing significant unmet medical needs in fungal infections and oncology, positioning itself as a leader in therapeutic innovation. With a diverse pipeline bolstered by strategic collaborations and a strong intellectual property portfolio, Viamet is well-prepared to advance its clinical initiatives and enhance shareholder value, aiming to redefine treatment approaches in its specialized therapeutic areas.
Compare with Other OTHER INDUSTRIAL METALS & MINING Stocks
Want to dig deeper into these stocks?